Brachyury: A new player in promoting breast cancer aggressiveness

Journal of the National Cancer Institute

Volumn 106, Issue 5, 2014, Pages

  Pires, Maira M ^a   Aaronson, Stuart A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYURY PROTEIN; T BOX TRANSCRIPTION FACTOR; TAMOXIFEN; UNCLASSIFIED DRUG; FETOPROTEIN;

ADJUVANT THERAPY; AGGRESSIVENESS; BREAST; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOMA; BREAST FIBROADENOMA; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; DISTANT METASTASIS; DOWN REGULATION; EDITORIAL; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KAPLAN MEIER METHOD; MONOTHERAPY; MRNA EXPRESSION ASSAY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR PROMOTION; UPREGULATION; BIOSYNTHESIS; FEMALE; METABOLISM; NOTE; PATHOLOGY;

BREAST NEOPLASMS; FEMALE; FETAL PROTEINS; HUMANS; T-BOX DOMAIN PROTEINS;

EID: 84905172130     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju094     Document Type: Editorial

References (34)

1. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008;14(24):7988-7999.
2. US Breast Cancer Statistics. http://breastcancer.org. Accessed March 27, 2014.
3. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mes-enchymal transitions. Biochem Pharmacol. 2000;60(8):1091-1099.
4. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchy-mal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973-981.
5. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-1428.
6. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429-1437.
7. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009;119(6):1417-1419.
8. Thiery J P, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-890.
9. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679-695.
10. Sleeman J P, Thiery J P. SnapShot: The epithelial-mesenchymal transition. Cell. 2011;145(1):162 e161.
11. Dobrovolskaia-Zavadskaia N. Sur la mortification spontanee de la queue chez la souris nouveau-nee et sur l'existence d'un caractere heriditaire "non-viable." C R Soc Biol. 1927;97:114-116.
12. Wilson V, Conlon FL. The T-box family. Genome Biol. 2002;3(6):REVI EWS3008.
13. Atreya I, Schimanski CC, Becker C, et al. The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. Gut. 2007;56(11):1572-1578.
14. Arnold SJ, Hofmann UK, Bikoff EK, Robertson EJ. Pivotal roles for eomesodermin during axis formation, epithelium-to-mesenchyme transition and endoderm specification in the mouse. Development. 2008;135(3):501-511.
15. Takeichi M, Nimura K, Mori M, Nakagami H, Kaneda Y. The transcription factors Tbx18 and Wt1 control the epicardial epithelial-mesenchymal transition through bi-directional regulation of Slug in murine primary epi-cardial cells. PloS One. 2013;8(2):e57829.
16. Cai X, Nomura-Kitabayashi A, Cai W, Yan J, Christoffels VM, Cai CL. Myocardial Tbx20 regulates early atrioventricular canal formation and endocardial epithelial-mesenchymal transition via Bmp2. Develop Biol. 2011;360(2):381-390.
17. Rowley M, Grothey E, Couch FJ. The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2004;9(2):109-118.
18. Sinclair CS, Adem C, Naderi A, et al. TBX2 is preferentially amplified in BRCA1-and BRCA2-related breast tumors. Cancer Res. 2002;62(13):3587-3591.
19. Wang B, Lindley LE, Fernandez-Vega V, Rieger ME, Sims AH, Briegel KJ. The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells. PloS One. 2012;7(7):e41355.
20. Jacobs JJ, Keblusek P, Robanus-Maandag E, et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet. 2000;26(3):291-299.
21. Rodriguez M, Aladowicz E, Lanfrancone L, Goding CR. Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res. 2008;68(19):7872-7881.
22. Burgucu D, Guney K, Sahinturk D, et al. Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma. BMC Cancer. October 19, 2012;12:481.
23. Humtsoe JO, Koya E, Pham E, et al. Transcriptional profiling identifies upregulated genes following induction of epithelial-mesenchymal transition in squamous carcinoma cells. Exp Cell Res. 2012;318(4):379-390.
24. Fan W, Huang X, Chen C, Gray J, Huang T. TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Cancer Res. 2004;64(15):5132-5139.
25. Yarosh W, Barrientos T, Esmailpour T, et al. TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacety-lases. Cancer Res. 2008;68(3):693-699.
26. Palena C, Roselli M, Litzinger MT, et al. Brachyury, an EMT driver, is overexpressed in breast carcinomas and associates with poor prognosis. J Natl Cancer Inst. 2014;106(5): dju054 doi:10.1093/jnci/dju054.
27. Cheng Q, Chang J T, Geradts J, et al. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. 2012;4(2):R62.
28. Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA. Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomarker Insights. February 9, 2010;5:9-20.
29. Taylor CR, Levenson RM. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006;49(4):411-424.
30. Palena C, Fernando RI, Hamilton DH. An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition. Oncoimmunology. 2014;3(1):e27220.
31. Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C. Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas. Semin Oncol. 2012;39(3):358-366.
32. Hamilton DH, Litzinger MT, Jales A, et al. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recom-binant brachyury-yeast vaccine. Oncotarget. 2013;4(10):1777-1790.
33. Palena C, Polev DE, Tsang KY, et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res. 2007;13(8):2471-2478.
34. ClinicalTrials.gov. Open Label Study to Evaluate the Safety and Tolerability of GI-6301 a Vaccine Consisting of Whole Heat-Killed Recombinant Yeast Genetically Modified to Express Brachyury Protein in Adults with Solid Tumors. http://www.clinicaltrials.gov/ct2/show/results/NCT01519817. Accessed March 27, 2014.